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The problem of resistance of malignant tumors to 
platinum compounds remains a challenge of modern 
clinical and experimental oncology. Among the main 
causes of low susceptibility of tumor cells to platinum-
containing agents are the decreased intracellular ac-
cumulation, the elevated glutathione S-transferase and 
metallothionein activities, the activation of DNA repair 
system [1–4]. The development of the novel pharma-
ceutical forms of platinum-containing agents providing 
their increased accumulation in tumor cells has been 
considered to be useful to overcome cisplatin-resistance 
[5]. The development of liposomal forms of cisplatin may 
be regarded as an advantageous approach [6, 7].
The parameters of pharmacokinetics and bioavail-
ability of cisplatin after intravenous and oral admi-
nistration have been assessed in the clinical studies 
[8]. The experimental studies have demonstrated the 
elevated bioavailability of liposomal forms of various 
antitumor drugs [9–11].
Earlier we have shown the different therapeutic 
activity of free and liposomal cisplatin in vivo (cisplatin-
sensitive and cisplatin-resistant Guerin carcinoma) 
[12, 13]. Our data have revealed the higher efficacy of 
liposomal form of cisplatin for treatment of resistant 
form of Guerin carcinoma.
The present study was aimed to analyze the relation 
between pharmacokinetics of cisplatin in liposomal 
form and its efficacy toward cisplatin-resistant and 
cisplatin-sensitive variants of Guerin carcinoma. Cis-
platin in the basic pharmaceutical form was used as 
a reference preparation.
MATERIALS AND METHODS
100 female Wistar rats with body weight of 150 ± 
5 g were used. All experiments performed according 
to the international guidelines of work with labora-
tory animals were approved by Bioethics Committee 
of R.E. Kavetsky IEPOR NASU (Kyiv, Ukraine).
Cisplatin resistance in tumors was generated by 
12 sequential transplantations of tumor cells in ani-
mals treated with cisplatin. Tumors were transplanted 
subcutaneously into interscapular region by injection 
of 0.5 ml of tumor cell suspension (2 × 106 cells per 
animal). Cisplatin for infusions (Ebewe, Austria), and 
its liposomal form as lyophilized powder for prepara-
tion of infusion solution (by 0.01 g, CAS Biolik, Kharkiv, 
Ukraine) were used.
Animals with transplanted cisplatin sensitive (CpS-
GC) and cisplatin resistant (CpRGC) strains of Guerin 
carcinoma, were housed in the following groups: 
1) animals with CpSGC treated with liposomal form of 
cisplatin (LCp); 2) animals with CpSGC treated with 
free cisplatin (FCp); 3) animals with CpSGC not treated 
with cytastatics — control group for CpSGC; 4) animals 
with CpRGC treated with LCp; 5) animals with CpRGC 
treated with FCp; 6) animals with CpRGC not treated 
with cytostatics — control group for CpRGC.
When the transplanted tumors reached the volume 
of 0.3 cm3, the animals from respective groups with 
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CpSGC and CRGC received 5 injections of LCp and 
FCp at a dose of 1.2 mg/kg body weight (every two 
days, 5 injections in total). The samples of blood se-
rum, liver, kidneys, lungs, and tumor tissue were taken 
in 0.25 h; 0.5 h; 1 h; 3 h; 6 h, and 24 h after LCp and 
FCp administration.
Assessment of cisplatin concentration. Con-
centration of cisplatin after its single administration 
in liposomal or basic pharmaceutical forms was as-
sessed in blood serum, tissues of tumor, kidneys, 
liver, and lungs of rats with CpSGC and CpRGC. For 
this purpose, tissue samples were mineralized by the 
method of dry cineration [14]. The concentration of 
platinum was measured by atomic absorption spectro-
photometry (С115М1 “Selmi”, Ukraine) by calibrating 
curve for platinum standards (Fluka, Switzerland) at 
the range of studied concentrations.
Analysis of cisplatin biodistribution in rat 
body. Biodistribution of cisplatin (in different phar-
maceutical forms) in body of animals with CpSGC and 
CpRGC variants was characterized by the following 
pharmacokinetic parameters: AUC-24 — area under 
pharmacokinetic curve determined in one day after ad-
ministration of the drug; Сmax — maximal concentration 
of cisplatin during observation period; ke — elimination 
constant of cisplatin calculated based on the dynam-
ics of cisplatin concentration in time period between 
1 h to 24 h using nonlinear regression analysis. Area 
under pharmacokinetic curve was calculated by the 
trapezium method according to the formula:
 i = 5
AUC = ∑(Ci + Ci + 1) × (ti + 1 – ti) / 2
 i = 1
wherein ti — time point of measuring cisplatin concen-
tration in animal’s body counted from the moment of 
drug administration; Ci — concentration of cisplatin at ti.
Statistical analysis was performed with the use of 
descriptive statistics as well as Student’s and Whitney 
tests and Statistica program.
RESULTS AND DISCUSSION
Cisplatin in both pharmaceutical forms has been 
shown to inhibit effectively the growth of the original 
variant of Guerin carcinoma. As shown in Fig. 1, even 
on the first day after the beginning of cisplatin adminis-
tration, the suppression of tumor growth was similar for 
both forms (FCp and LCp). The LCp efficacy assessed 
upon termination of the treatment was very high with 
tumor growth inhibition (TGI) indices being 99.0% and 
99.4% for LCp and FCp, respectively (Table 1).
Table 1. Tumor weight and tumor growth inhibition indices after treatment with 
cisplatin in different pharmaceutical forms on Day 20 after tumor transplantation
Variant 
of Guerin 
carcinoma
Control animals LCp FCp
Tumor weight (g)
TGI (%)
Tumor weight (g)
TGI (%)М m М m М m
Sensitive 35.3 5.8 0.4 0.1 99.0 0.2 0.08 99.4
Resistant 50.4 4.2 13.8 2.1 72.6 35.3 4.7 30,0
The inhibition of CpRGC growth by both pharmaceu-
tical forms of cisplatin was significantly lower as com-
pared with the inhibition of the original variant of tumor 
(see Fig. 1, Table 1). As far as cisplatin is a cycle-specific 
anticancer drug, its lower efficacy toward CpRGC is 
in part associated with lower growth rate of the tumor 
compared to the original (CpSGC) tumor strain.
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Fig. 1. Growth kinetics of CpSGC (a) and CpRGC (b) variants with 
and without therapy with cisplatin in different pharmaceutical forms
Analysis of CpRGC growth kinetics has shown that 
growth inhibition of resistant tumor variant by cisplatin 
both in free and liposomal forms became evident only 
one week after the initiation of the treatment. The ef-
fects of LCp were more pronounced as compared with 
FCp. At the end of LCp therapy, tumor volume was 
3 times as less as that upon FCp treatment (see Fig. 1), 
with TGI indices being 72.6% and 30% for LCp and 
FCp, respectively. Therefore, an antitumor efficacy of 
cisplatin in liposomal form toward CpRGC variant ex-
ceeded significantly that of FCp. In contrast, both LCp 
and FCp demonstrated the similar efficacy in CpSGC 
variant of Guerin carcinoma.
The pharmacokinetic studies have shown that such 
differences in sensitivity of resistant variant to cisplatin 
in different pharmaceutical forms are largely attributed 
to the differences in cisplatin biodistribution in rat body. 
Fig. 2 shows three-phase pattern of the dynamics of cis-
platin concentrations (in both pharmaceutical forms) in 
blood serum of rats bearing CpSGC or CpRGC variants 
after intraperitoneal administration of the drug. After 
absorption of the drug (the first phase with duration 
<1 h), the relatively short phase of cisplatin distribu-
tion followed by the prolonged phase of its elimination 
are observed. The area under pharmacokinetic curve 
of LCp one day after its administration practically 
doesn’t depend on the degree of sensitivity of Guerin 
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carcinoma. AUC24 for LCp in rats with CpRGC or CpSGC 
variant doesn’t differ significantly (Table 2). In contrary, 
the area under pharmacokinetic curve of FCp in animals 
with CpRGC variant was by 70% less (p < 0.001) as 
compared to the sensitive strain.
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Fig. 2. Dynamics of cisplatin concentration in blood serum of rats 
with CpSGC (a) and CpRGC (b)
Table 2. Pharmacokinetic parameters of cisplatin (FCp and LCp) in blood 
serum of rats with CpSGC and CpRGC
Pharmacokinetic 
parameters
Sensitive variant of Guerin 
carcinoma
Resistant variant of Guerin 
carcinoma
LCp FCp LCp FCp
AUC24 (μg × h/L) 63.3 ± 10.2* 163.9 ± 30.8 45.1 ± 7.1 49.8 ± 8.9
Сmax (μg/L) 29.4 ± 2.2* 16.3 ± 1.3 5.6 ± 0.5 8.3 ± 2.2
Кel (h–1) 0.03 ± 0.004* 0.08 ± 0.002 0.11 ± 0.02* 0.28 ± 0.1
*The differences are significant (p < 0.05) as compared with FCp.
For CpRGC-bearing rats, LCp and FCp are bio-
equivalent: there is no statistically significant diffe-
rence between area under pharmacokinetic curve 
and maximal concentration of the drugs. For CpSGC-
bearing rats, AUC24 for LCp is less by 61%, and Сmax — 
higher by 80% as compared with respective FCp data.
One should pay attention to the significant decrease 
of elimination constant of cisplatin in liposomal form as 
compared with free one from blood serum of rats bear-
ing either CpRGC or CpSGC tumors. Also the half-life of 
liposomal cisplatin in animals’ blood increases as well 
as the ratio between the area under pharmacokinetic 
curve (calculated at t > 1 day) for liposomal cisplatin 
(AUCt(LCp)) to AUCt(FCp) of free form, so:
 AUCt(LCp)   AUC24(LCp)—————— > ——————
 AUCt(FCp)   AUC24(FCp)
This fact seems to be important because half-life 
increase of liposomal cisplatin in blood provides for its 
accumulation in tissues with low level of vascularization, 
including the tumor itself. And the data on dynamics 
of cisplatin concentrations in tumor tissue have in fact de-
monstrated the trend (regarding the average values) for 
higher AUC24 values of LCp compared with FCp (Table 3).
Table 3. Pharmacokinetic parameters of cisplatin in tumor tissue of rats 
with Guerin carcinoma
Pharmacokinetic 
parameters
Sensitive variant of Guerin 
carcinoma
Resistant variant of Guerin 
carcinoma
LCp FCp LCp FCp
AUC24 (μg × h/L) 74.3 ± 7.3* 57.9 ± 7.1 40.5 ± 3.1* 33.2 ± 2.8
*The differences are significant (p < 0.05) as compared with FCp.
It’s necessary to note that the dynamics of cisplatin 
concentration in tumor tissue of CpRGC-bearing rats is 
characterized by 90% higher level (p < 0.05) in 24 h after 
LCp administration as compared with FCp (Fig. 3). Be-
ing in line with such biodistribution of cisplatin in tumor 
tissue, continuous injections of the drug will result in 
the increased area under pharmacokinetic curve after 
LCp administration as compared with FCp, and this 
fact could explain higher antitumor activity of liposomal 
cisplatin compared to its free form toward CpRGC.
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Fig. 3. Dynamics of cisplatin concentration in tumor tissue of rats 
with CpSGC (a) and CpRGC (b)
It is known that an effectiveness of antitumor 
activity of cisplatin is significantly limited by its neph-
rotoxicity, which is directly correlated with maximal 
concentration of cisplatin in the kidneys and the 
amount of the drug that passes through the kidneys. 
Analysis of cisplatin biodistribution in the kidneys has 
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shown that its concentration after FCp administration 
was significantly higher at all stages (independently 
of tumor type) compared with the respective indices 
of liposomal form (Fig. 4, Table 4). Along with this, 
for LCp, AUC24 indices were by 68.6% (p < 0.01) and 
50.7% (p < 0.05) lower than AUC24 indexes for FCp in 
kidneys of rats with CpRGC and CpSGC, respectively.
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Fig. 4. Dynamics of cisplatin concentration in kidney tissue 
of rats with CpSGC (a) and CpRGC (b)
Table 4. Pharmacokinetic parameters of cisplatin in kidneys of rats with 
Guerin carcinoma
Pharmacokinetic 
parameters
Sensitive variant of Guerin 
carcinoma
Resistant variant of Guerin 
carcinoma
LCp FCp LCp FCp
AUC24 (μg × h/L) 173.4 ± 26.0* 351.7 ± 52.8 176.0 ± 26.4* 560.5 ± 84.1
Сmax (μg/L) 17.2 ± 0.21 29.0 ± 0.42 22.6 ± 0.20 26.4 ± 0.68
*The differences are significant (p < 0.05) as compared with FCp.
Therefore, cisplatin in liposomal form shows higher 
efficacy toward resistant variant of Guerin carcinoma 
and lower nephrotoxicity than the drug in free phar-
maceutical form.
Analysis of biodistribution of cisplatin in both 
pharmaceutical forms in liver and lung tissues of rats 
with CpSGC and CpRGC did not reveal significant 
differences (Table 5). One could observe only 33% 
decrease (p < 0.05) of AUC24 of FCp in lung tissues of 
rats with CpRGC compared to that for liposomal form.
The results allow one to consider that cisplatin in 
liposomal form possesses higher specificity of antitu-
mor action than free cisplatin. For cisplatin-sensitive 
tumors, such increased specificity of LCp preparation 
is specified by significant decrease of its nephrotoxicity, 
while in the case of cisplatin-resistant tumors — by sig-
nificantly higher (compared to the basic form) efficacy 
of its antitumor action as well as lower nephrotoxicity.
Table 5. Pharmacokinetic parameters of cisplatin in liver and lungs of rats 
with Guerin carcinoma
Pharmacokinetic 
parameters
Sensitive variant of Guerin 
carcinoma
Resistant variant of Guerin 
carcinoma
LCp FCp LCp FCp
Liver
AUC24 (μg × h/L) 14.29 ± 2.14 15.6 ± 2.3 16.7 ± 2.5 17.0 ± 2.5
Lungs
AUC24 (μg × h/L) 22.9 ± 3.4 28.3 ± 4.2 21.91 ± 3.3 18.9 ± 2.8
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